Antibodies to VEGF-C

Details Antibodies to VEGF-C Antibodies to VEGF-C

2008-09-09

2008-09-09

O'Hara, Eileen B. (Department: 1646)

Chemistry: natural resins or derivatives; peptides or proteins;

Proteins, i.e., more than 100 amino acid residues

Blood proteins or globulins, e.g., proteoglycans, platelet...

C530S388100, C530S387900, C530S391100, C424S139100, C424S141100

Reexamination Certificate

active

10792461

ABSTRACT:
Provided are purified and isolated VEGF-C polypeptides capable of binding to at least one of KDR receptor tyrosine kinase (VEGFR-2) and Flt4 receptor tyrosine kinase (VEGFR-3); analogs of such peptides that have VEGF-C-like or VEGF-like biological activities or that are VEGF or VEGF-C inhibitors; polynucleotides encoding the polypeptides; vectors and host cells that embody the polynucleotides; pharmaceutical compositions and diagnostic reagents comprising the polypeptides; and methods of making and using the polypeptides.

REFERENCES:
patent: 4959314 (1990-09-01), Mark et al.
patent: 5219739 (1993-06-01), Tischer et al.
patent: 5326695 (1994-07-01), Andersson et al.
patent: 5332671 (1994-07-01), Ferrara et al.
patent: 5607918 (1997-03-01), Eriksson et al.
patent: 5776755 (1998-07-01), Alitalo et al.
patent: 5932540 (1999-08-01), Hu et al.
patent: 5935820 (1999-08-01), Hu et al.
patent: 6040157 (2000-03-01), Hu et al.
patent: 6107046 (2000-08-01), Alitalo et al.
patent: 6130071 (2000-10-01), Alitalo et al.
patent: 6221839 (2001-04-01), Alitalo et al.
patent: 6245530 (2001-06-01), Alitalo et al.
patent: 6361946 (2002-03-01), Alitalo et al.
patent: 6403088 (2002-06-01), Alitalo et al.
patent: 6451764 (2002-09-01), Lee et al.
patent: 6824777 (2004-11-01), Alitalo et al.
patent: 7109308 (2006-09-01), Rosen et al.
patent: 2002/0164667 (2002-11-01), Alitalo et al.
patent: 2003/0026759 (2003-02-01), Ferrell et al.
patent: 2003/0166873 (2003-09-01), Lee et al.
patent: 2004/0213790 (2004-10-01), Lee et al.
patent: 2006/0121025 (2006-06-01), Lee et al.
patent: 0 506 477 (1992-03-01), None
patent: WO 91/09955 (1991-07-01), None
patent: WO 92/20808 (1992-11-01), None
patent: WO 94/12650 (1994-06-01), None
patent: WO 95/24473 (1995-09-01), None
patent: WO 95/26364 (1995-10-01), None
patent: WO 95/33050 (1995-12-01), None
patent: WO 95/33772 (1995-12-01), None
patent: WO 96/11269 (1996-04-01), None
patent: WO 96/30046 (1996-10-01), None
patent: WO 96/39421 (1996-12-01), None
patent: WO 96/39515 (1996-12-01), None
patent: WO 97/05250 (1997-02-01), None
patent: WO 97/09427 (1997-03-01), None
patent: WO 97/17442 (1997-05-01), None
patent: WO 98/49300 (1997-06-01), None
patent: WO 98/02543 (1997-07-01), None
patent: WO 99/46364 (1999-09-01), None
patent: WO 00/21560 (2000-04-01), None
patent: WO 00/24412 (2000-05-01), None
patent: WO 00/58511 (2000-10-01), None
patent: WO/02/083704 (2002-10-01), None
patent: WO/02/083849 (2002-10-01), None
patent: WO/2005/087812 (2005-09-01), None
U.S. Appl. No. 60/003,491, filed Sep. 8, 1995, James Lee et al.
U.S. Appl. No. 08/554,374, filed Nov. 8, 1995, Lyman, S.
U.S. Appl. No. 08/601,132, filed Feb. 14, 1996, Alitalo et al.
U.S. Appl. No. 08/671,573, filed Jun. 28, 1996, Alitalo et al.
Achen, M.G. et al., “Vascular Endothelial Growth Factor D (VEGF-D) is a Ligand for the Tyrosine Kinases VEGF Receptor 2 (Flk1) and VEGF Receptor 3 (Flt4),”Proceedings of the National Academy of Science, USA, 95:548-553 (Jan. 1998).
Adams, M.D. et al., “Initial assessment of human gene diversity and expression patterns based upon 83 million nucleotides of cDNA sequence,”Nature, 377(6547Supplement):3-174 (Sep. 1995).
Alitalo et al., “Vascular Endothelial Growth Factors and Receptors Involved in Angiogenesis,”The 9th International Conference of the International Society of Differentiation(ISD),Development, Cell Differentiation and Cancer, Pisa (Italy), Sep. 28-Oct. 2, 1996, p. 66 (ABSTRACT S22).
Alitalo et al., “Vascular Endothelial Growth Factors B and C Receptors Involved in Angiogenesis,”German-American Academic Council Foundation(GAAC)/Stiftung Deutsch-Amerikanisches Akademisches Konzil(DAAK),2nd Symposium on Current Problems in Molecular Medicine: The Role of Cytokines in Human Disease, Nov. 17-20, 1996, Ringberg Castle, Germany, p. 1 (ABSTRACT).
Alitalo, K., “Vascular Endothelial Growth Factors B and C and Receptors Involved in Angiogenesis,”IX International Vascular Biology Meeting, Seattle, Washington, USA, Sep. 4-8, 1996, p. 1 (ABSTRACT).
Anderson, W.F., Scientific American, pp. 124-128, Sep. 1995.
Andersson et al., “Assignment of Interchain Disulfide Bonds in Platelet-Derived Growth Factor (PDGF) and Evidence for Agonist Activity of Monomeric PDGF,”J. Biol. Chem., 267(16):11260-11266 (Jun. 5, 1992).
Aprelikova et al., “FLT4, A Novel Class III Receptor Tyrosine Kinase in Chromosome 5q33-qter,”Cancer Research, 52:746-748 (Feb. 1, 1992).
Asahara et al., Isolation of Putative Progenitor Endothelial Cells for Angiogenesis,Science, 275: 964-967 (Feb. 1997).
Auffray et al.H. sapienspartial cDNA sequence; clone c-1wfl1. EST-STS Accession No. Z44272. Nov. 6, 1994.
Ausprunk, et al., “Migration and Proliferation of Endothelial Cells in Preformed and Newly Formed Blood Vessels during Tumor Angiogenesis,”Microvasc. Res., 14:53-65 (1977).
Basilico et al., “The FGF Family of Growth Factors and Oncogenes,”Adv. Cancer Res., 59:145-165 (1992).
Berse et al., “Vascular Permeability Factor (Vascular Endothelial Growth Factor( Gene is Expressed Differentially in Normal Tissues, Macrophages, and Tumors,”Mol. Biol. Cell., 3:211-220 (Feb, 1992).
Betsholtz et al., “cDNA Sequence and Chromosomal Localization of Human Platelet-Derived Growth Factor A-Chain and Its Expression in Tumor Cell Lines,”Nature, 320:695-699 (Apr. 1986).
Blau et al., The New England Journal of Medicine, p. 1204-1207, Nov. 2, 1995.
Böhling, T. et al., “Expression of Growth Factors and Growth Factor Receptors in Capillary Hemangioblastoma,”J. Neuropathol. Exp. Neurol., 55:522-527 (1996).
Borg et al., “Biochemical Characterization of Two Isoforms of FLT4, a VEGF Receptor-Related Tyrosine Kinase,”Oncogene, 10:973-84 (1995).
Bowie et al., “Deciphering the Message in Protein Sequences: tolerance to amino acid substitutions,”Science, 247:1306-1310 (Mar. 16, 1990).
Breier et al., “Expression of Vascular Endothelial Growth Factor During Ebryonic Angiogenesis and Endothelial Cell Differentiation,”Development, 114:521-532 (1992).
Cao et al., “Heterodimers of Placenta Growth Factor/Vascular Endothelial Growth Factor,”J. Biol. Chem., 271(6):3154-3162 (Feb. 9, 1996).
Cao, Y. et al., “Vascular Endothelial Growth Factor-C Induces Angiogenesis in Vivo,”Proc. Natl. Acad . . . Sci., 95:14389-14394 (1998).
Capecchi, M.R., “Altering the Genome by Homologous Recombination,”Science, 244:1288-1292 (Jun. 16, 1989).
Chen and Shyu, “Selective Degradation of Early-Response-Gene mRNAs: Functional Analyses of Sequence Features of the A U-Rich Elements,”Mol. Cell Biol., 14(12):8471-8482 (Dec. 1994).
Cheng and Flanagan, “Identification and Cloning of ELF-1, A Developmentally Expressed Ligand for the Mek4 and Sek Receptor Tyrosine Kinases,”Cell, 79:157-168 (Oct. 7, 1994).
Chilov, D. et al., “Genomic Organization of Human and Mouse Genes for Vascular Endothelial Growth Factor C,”J. Biol. Chem., 272:25176-25183 (1997).
Claesson-Welsh et al., “Identification and Structural Analysis of the A Type Receptor for Platelet-derived Growth Factor,”J. Biol. Chem., 264(3):1742-1747 (Jan. 25, 1989).
Claesson-Welsh et al., “cDNA Cloning and Expression of a Human Platelet-Derived Growth Factor (PDGF) Receptor Specific for B-Chain-Containing PDGF Molecules,”Mol. Cell Biol., 8(8):3476-3486 (Aug. 1988).
Claesson-Welsh et al., “cDNA Cloning and Expression of the Human A-type Platelet-Derived Growth Factor (PDGF) Receptor Establishes Structural Similarity to the B-type PDGF Receptor,”Proc. Nat'l Acad. Sci., USA, 86(13):4917-4921 (Jul. 1989).
Coffin et al., “Angioblast Differentiation and Morphogenesis of the Vascular Endothelium in the Mouse Embryo,”Devel. Biol., 148:51-62 (1991).
Cohen, T. et al., “VEGF121, A Vascular Endothelial Growth Factor (VEGF) Isoform Lacking Heparin Binding Ability, Requires Cell-Surface Heparan

Affiliated with

Also associated with

Rating

Antibodies to VEGF-C does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Antibodies to VEGF-C, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antibodies to VEGF-C will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3959506